Parkinson's Disease Treatment Pipeline Holds Significant Potential for Patients and Investors
The Parkinson's disease pipeline presents a distinctly different and promising landscape from the current market, which relies heavily on the use of symptomatic treatment in the form of neuromodulators. The pipeline is highly active, consisting of 365 programs across all stages of development, and a diverse range of molecular targets. It is also characterized by a high level of innovation compared to the CNS and the industry as a whole, with 43% of all pipeline programs with disclosed molecular targets...
View full press release